Testagen is a synthetic Khavinson peptide used in research settings to investigate testicular support and hormonal balance. Users typically run daily doses ranging from 100 µg to 5 mg, with 2 mg serving as the most common protocol. While the peptide is a subject of interest for its potential role in addressing hypogonadotropism, the evidence base remains thin, as most exploratory indications lack published results and all human use is currently off-label or compounded. Injection-site reactions, histamine responses, and systemic side effects have not been a consistent theme in community reports.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Human evidence for Testagen is limited — pilot studies, withdrawn trials, or completed trials without posted results. Off-label / exploratory data exists for 1 additional indication (Hypogonadotropism).
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Hypogonadotropism
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How Testagen is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No completed trial has been identified for Testagen, so no dosing figure has been reliably captured.
No structured protocol details captured for this tier yet.
Of nine community reports, five dose daily subQ at around 2 mg, with individual doses ranging from 100 mcg to 5 mg. The remaining four didn't report a schedule; their doses centered near 500 mcg.